Peripheral tolerance limits CNS accumulation of CD8 T cells specific for an antigen shared by tumor cells and normal astrocytes

GLIA

Volumn 56, Issue 15, 2008, Pages 1625-1636

  Calzascia, Thomas ^a,d   Loh, Jacelyn M S ^a   Di Berardino Besson, Wilma ^a   Masson, Frédérick ^a,e   Guillaume, Philippe ^b   Burkhardt, Karim ^a   Herrera, Pedro L ^c   Dietrich, Pierre Yves ^a   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Autoimmunity; Brain tumor immunology; Immune privilege; Immunotherapy; Regional immunity

Indexed keywords

AUTOANTIGEN; TUMOR ANTIGEN;

ANIMAL; ARTICLE; ASTROCYTE; ASTROCYTOMA; AUTOIMMUNITY; BRAIN; BRAIN TRANSPLANTATION; BRAIN TUMOR; CD8+ T LYMPHOCYTE; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEUROLOGIC DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, NEOPLASM; ASTROCYTES; ASTROCYTOMA; AUTOANTIGENS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; AUTOIMMUNITY; BRAIN; BRAIN NEOPLASMS; BRAIN TISSUE TRANSPLANTATION; CD8-POSITIVE T-LYMPHOCYTES; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; TUMOR CELLS, CULTURED;

EID: 61549119830     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.20715     Document Type: Article

References (51)

1. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. 2005. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043-6053.
2. Borrow P, Cornell JL, Ruppe MD, Mucke L. 1995. Immunizationinduced inflammatory infiltration of the central nervous system in transgenic mice expressing a microbial antigen in astrocytes. J Neuroimmunol 61:133-149.
3. Brandle D, Bilsborough J, Rulicke T, Uyttenhove C, Boon T, van den Eynde BJ. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28:4010-4019.
4. Bush TG, Savidge TC, Freeman TC, Cox HJ, Campbell EA, Mucke L, Johnson MH, Sofroniew MV. 1998. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 93:189-201.
5. Cabarrocas J, Bauer J, Piaggio E, Liblau R, Lassmann H. 2003. Effective and selective immune surveillance of the brain by MHC class Irestricted cytotoxic T lymphocytes. Eur J Immunol 33:1174-1182.
6. Cabarrocas J, Piaggio E, Zappulla JP, Desbois S, Mars LT, Lassmann H, Liblau RS. 2004. A transgenic mouse model for T-cell ignorance of a glial autoantigen. J Autoimmun 22:179-189.
7. Calzascia T, Masson F, Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M, Ruegg C, Dietrich PY, Walker PR. 2005. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22:175-184.
8. Casanova JL, Cerottini JC, Matthes M, Necker A, Gournier H, Barra C, Widmann C, MacDonald HR, Lemonnier F, Malissen B. 1992. H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity. J Exp Med 176:439-447.
9. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. 1992. Differential expression of transforming growth factorβ1, -β2, and -β3 by glioblastoma cells, astrocytes, and microglia. J Immunol 148:1404-1410.
10. Cornet A, Savidge TC, Cabarrocas J, Deng WL, Colombel JF, Lassmann H, Desreumaux P, Liblau RS. 2001. Enterocolitis induced by autoimmune targeting of enteric glial cells: A possible mechanism in Crohn's disease? Proc Natl Acad Sci USA 98:13306-13311.
11. Cserr HF, Knopf PM. 1992. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: A new view. Immunol Today 13:507-512.
12. da Cunha A, Vitkovic L. 1992. Transforming growth factor-beta 1 (TGF-β 1) expression and regulation in rat cortical astrocytes. J Neuroimmunol 36:157-169.
13. Ehtesham M, Black KL, Yu JS. 2004. Recent progress in immunotherapy for malignant glioma: Treatment strategies and results from clinical trials. Cancer Control 11:192-207.
14. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH. 2006. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294-3302.
15. Fontana A, Fierz W, Wekerle H. 1984. Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307:273-276.
16. Guinn BA, Kasahara N, Farzaneh F, Habib NA, Norris JS, Deisseroth AB. 2007. Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther 15:1065-1071.
17. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K. 2005. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466.
18. Hussain SF, Heimberger AB. 2005. Immunotherapy for human glioma: Innovative approaches and recent results. Expert Rev Anticancer Ther 5:777-790.
19. Joshi BH, Plautz GE, Puri RK. 2000. Interleukin-13 receptor alpha chain: A novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res 60:1168- 1172.
20. Klein MA, Ruedi D, Nozaki M, Dell EW, Diserens AC, Seelentag W, Janzer RC, Aguzzi A, Hegi ME. 2000. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene 19:5329-5337.
21. + T cells. J Exp Med 186:239-245.
22. Kwidzinski E, Bunse J, Kovac AD, Ullrich O, Zipp F, Nitsch R, Bechmann I. 2003. IDO (indolamine 2,3-dioxygenase) expression and function in the CNS. Adv Exp Med Biol 527:113-118.
23. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. 2005. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515- 5525.
24. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. 2004. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64:4980-4986.
25. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
26. Magnusson FC, Liblau RS, von Boehmer H, Pittet MJ, Lee JW, Turley SJ, Khazaie K. 2008. Direct presentation of antigen by lymph node stromal cells protects against CD8 T-cell-mediated intestinal autoimmunity. Gastroenterology 134:1028-1037.
27. Matsumoto Y, Hanawa H, Tsuchida M, Abo T. 1993. In situ inactivation of infiltrating T cells in the central nervous system with autoimmune encephalomyelitis. The role of astrocytes. Immunology 79:381-390.
28. Matsumoto Y, Ohmori K, Fujiwara M. 1992. Immune regulation by brain cells in the central nervous system: Microglia but not astrocytes present myelin basic protein to encephalitogenic T cells under in vivo-mimicking conditions. Immunology 76:209-216.
29. McPherson SW, Yang J, Chan CC, Dou C, Gregerson DS. 2003. Resting CD8 T cells recognize β-galactosidase expressed in the immune-privileged retina and mediate autoimmune disease when activated. Immunology 110:386-396.
30. Mitchell DA, Fecci PE, Sampson JH. 2003. Adoptive immunotherapy for malignant glioma. Cancer J 9:157-166.
31. Morgan DJ, Kreuwel HT, Sherman LA. 1999. Antigen concentration and precursor frequency determine the rate of CD81 T cell tolerance to peripherally expressed antigens. J Immunol 163:723-727.
32. Nott A, Meislin SH, Moore MJ. 2003. A quantitative analysis of intron effects on mammalian gene expression. RNA 9:607-617.
33. Okayama H, Berg P. 1992. A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells. 1983. Biotechnology 24:270-279.
34. Opsahl ML, McClenaghan M, Springbett A, Reid S, Lathe R, Colman A, Whitelaw CB. 2002. Multiple effects of genetic background on variegated transgene expression in mice. Genetics 160:1107-1112.
35. Raeber AJ, Race RE, Brandner S, Priola SA, Sailer A, Bessen RA, Mucke L, Manson J, Aguzzi A, Oldstone MB, Weissmann C, Chesebro B. 1997. Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO J 16:6057-6065.
36. Redwine JM, Buchmeier MJ, Evans CF. 2001. In vivo expression of major histocompatibility complex molecules on oligodendrocytes and neurons during viral infection. Am J Pathol 159:1219-1224.
37. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY. 1997. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J Clin Invest 99:1173-1178.
38. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V. 2007. Expression of nine tumour antigens in a series of human glioblastoma multiforme: Interest of EGFRvIII, IL-13Ra2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81:139-148.
39. Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H. 2007. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res 67:6451-6458.
40. Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. 2006. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2:494-503.
41. Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, Cairncross JG. 2006. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11:165- 180.
42. Suter T, Biollaz G, Gatto D, Bernasconi L, Herren T, Reith W, Fontana A. 2003. The brain as an immune privileged site: Dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol 33:2998-3006.
43. Ueda R, Low KL, Zhu X, Fujita M, Sasaki K, Whiteside TL, Butterfield LH, Okada H. 2007. Spontaneous immune responses against gliomaassociated antigens in a long term survivor with malignant glioma. J Transl Med 5:68.
44. Walker PR, Calzascia T, de Tribolet N, Dietrich PY. 2003. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42:97-122.
45. Walker PR, Calzascia T, Schnuriger V, Chalmers D, Saas P, Dietrich PY. 2000a. Loss of Fas (CD95/APO-1) expression by antigen-specific cytotoxic T cells is reversed by inhibiting DNA methylation. Cell Immunol 206:51-58.
46. Walker PR, Calzascia T, Schnuriger V, Scamuffa N, Saas P, de Tribolet N, Dietrich PY. 2000b. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells. J Immunol 165:3128-3135.
47. Weber F, Meinl E, Aloisi F, Nevinny-Stickel C, Albert E, Wekerle H, Hohlfeld R. 1994. Human astrocytes are only partially competent antigen presenting cells. Possible implications for lesion development in multiple sclerosis. Brain 117:59-69.
48. Weller M, Fontana A. 1995. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 21:128-151.
49. Williams A, Harker N, Ktistaki E, Veiga-Fernandes H, Roderick K, Tolaini M, Norton T, Williams K, Kioussis D. 2008. Position effect variegation and imprinting of transgenes in lymphocytes. Nucleic Acids Res 36:2320-2329.
50. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK, Chen W, Low WC. 2006. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76:23-30.
51. Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. 2006. Immunotherapy for patients with malignant glioma: From theoretical principles to clinical applications. Expert Rev Neurother 6:1481- 1494.